Dr. Joseph Geraci reports

NETRAAI STUDY ACCEPTED FOR PUBLICATION IN NPJ DIGITAL MEDICINE, PART OF THE NATURE PORTFOLIO

Netramark Holdings Inc.'s peer-reviewed paper, "Explainable AI-Driven Precision Clinical Trial Enrichment: Demonstration of the NetraAI Platform with a Phase II Depression Trial," has been accepted for publication in npj Digital Medicine, part of the Nature Portfolio.

The paper presents how Netramark's proprietary NetraAI platform applies explainable, mathematically grounded artificial intelligence to identify patient subpopulations that drive therapeutic response in small, heterogeneous clinical trial data sets. Using data from a National Institute of Mental Health phase 2 ketamine trial in treatment-resistant depression, NetraAI uncovered interpretable personas or model derived subgroups that may inform precision enrichment strategies across psychiatry and other therapeutic areas.

The research was co-written by investigators from the NIMH, part of the U.S. National Institutes of Health, including Dr. Elizabeth D. Ballard and Dr. Carlos A. Zarate Jr., alongside scientists from Netramark Corp. and academic collaborators. (NIMH participation does not imply endorsement by the U.S. government.)

"Acceptance of this paper for publication by npj Digital Medicine affirms the progress we've made toward building an AI engine purpose-built for clinical trials. Our work demonstrates a data-driven methodology with meaningful improvements in performance and clinical interpretability," said Dr. Joseph Geraci, chief scientific and technical officer of Netramark.

Dr. Luca Pani, chief innovation and regulatory officer at Netramark, added: "This publication bridges scientific innovation with the rigorous expectations of regulatory science. By embedding explainability, reproducibility and traceability into its core, NetraAI provides regulators and clinical investigators with credible tools designed to support modern clinical trial design and decision making."

The study highlights how NetraAI's integration of dynamical system modelling, long-range-memory feature learning and its ability to augment large language model explainability can enhance clinical trial decision making, reduce placebo interference and optimize trial enrichment.

About Netramark Holdings Inc.

Netramark is a company focused on being a leader in the development of generative artificial intelligence/machine learning solutions targeted at the pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows Netramark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activate traditional AI/ML methods. The result is that Netramark can work with much smaller data sets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.

We seek Safe Harbor.